Page last updated: 2024-12-06
trimethylcolchicinic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 453131 |
| CHEMBL ID | 517186 |
| MeSH ID | M0054896 |
| PubMed CID | 18999 |
| CHEMBL ID | 3729937 |
| CHEBI ID | 95161 |
| SCHEMBL ID | 1822222 |
| MeSH ID | M0054896 |
Synonyms (68)
| Synonym |
|---|
| MLS002153887 , |
| smr000112547 |
| BRD-K84300594-001-02-6 |
| colchiceine, n-deacetyl- |
| skf 284 |
| brn 3008992 |
| nsc 36796 |
| einecs 222-464-5 |
| colchiceine, n-deacetyl- (van) |
| benzo(a)heptalen-9(5h)-one, 7-amino-6,7-dihydro-10-hydroxy-1,2,3-trimethoxy-, (s)- |
| (s)-7-amino-6,7-dihydro-10-hydroxy-1,2,3-trimethoxybenzo(a)heptalen-9(5h)-one |
| NCGC00179572-01 |
| BPBIO1_000440 |
| PRESTWICK3_000580 |
| BSPBIO_000400 |
| benzo[a]heptalen-9(5h)-one, 7-amino-6,7-dihydro-10-hydroxy -1,2,3-trimethoxy-, (7s)- |
| n-deacetylcolchiceine |
| desacetylcolchiceine |
| (7s)-7-amino-10-hydroxy-1,2,3-trimethoxy-6,7-dihydro-5h-benzo[a]heptalen-9-one |
| 3482-37-9 |
| AB00513865 |
| CHEMBL517186 |
| HMS2096D22 |
| HMS2268E20 |
| AKOS015969698 |
| 4-14-00-00937 (beilstein handbook reference) |
| 333bvy614o , |
| unii-333bvy614o |
| (7s)-7-amino-6,7-dihydro-10-hydroxy-1,2,3-trimethoxy-benzo[a]heptalen-9(5h)-one |
| n-deacetyl colchiceine |
| (7s)-7-azanyl-1,2,3-trimethoxy-10-oxidanyl-6,7-dihydro-5h-benzo[a]heptalen-9-one |
| cid_453131 |
| bdbm79208 |
| colchicinic acid, o,o',o''-trimethyl- |
| benzo(a)heptalen-9(5h)-one, 7-amino-6,7-dihydro-10-hydroxy-1,2,3-trimethoxy-, (7s)- |
| (7s)-7-amino-9-hydroxy-1,2,3-trimethoxy-6,7-dihydrobenzo[a]heptalen-10(5h)-one |
| STL564563 |
| Q27256218 |
| AKOS037623125 |
| DTXSID701031742 |
| PRESTWICK2_000580 |
| trimethylcolchicinic acid |
| nsc36796 |
| deacetylcolchiceine |
| benzo[a]heptalen-9(5h)-one,7-dihydro-10-hydroxy-1,2,3-trimethoxy-, (s)- |
| colchicinic acid, trimethyl- |
| deacetylcholchiceine |
| wln: l b677 mv&t&j co1 do1 eo1 jz nq |
| nsc-36796 |
| desacetylcholchiceine |
| PRESTWICK_353 |
| OPREA1_221824 |
| PRESTWICK0_000580 |
| PRESTWICK1_000580 |
| SPBIO_002619 |
| 7-amino-10-hydroxy-1,2,3-trimethoxy-6,7-dihydro-5h-benzo[a]heptalen-9-one |
| FT-0665494 |
| HMS1569D22 |
| (r/s)-n-deacetyl colchiceine |
| 68296-64-0 |
| SCHEMBL1822222 |
| CHEMBL3729937 |
| CCG-231728 |
| CHEBI:95161 |
| FT-0665493 |
| DTXSID90875143 |
| Q27166959 |
| desacetylcolchiceine; n-deacetylcolchiceine; nsc 36796 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " In terms of dose-response demecolcine was slightly more effective than colchicine, but both were considerably more active than trimethylcolchicinic acid." | ( The role of microtubules in pinocytosis. Inhibition of fluid-phase pinocytosis in the rat visceral yolk sac by mitoclasic and related agents. Duncan, R; Lloyd, JB; Starling, D, 1983) | 0.47 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| cyclic ketone | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (13)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 79.4328 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 39.8107 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| IDH1 | Homo sapiens (human) | Potency | 29.0929 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 63.0957 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 63.0957 | 6.3096 | 60.2008 | 112.2020 | AID720707 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.8730 | 10.7219 | 78.4000 | AID493155 |
| sentrin-specific protease 8 | Homo sapiens (human) | IC50 (µMol) | 62.8500 | 0.0408 | 18.9292 | 94.8000 | AID624322; AID651559 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Other Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Skn7p | Saccharomyces cerevisiae (brewer's yeast) | AbsAC40_uM | 0.9360 | 0.6600 | 5.2696 | 18.2300 | AID624258 |
| aryl hydrocarbon receptor nuclear translocator | Homo sapiens (human) | AC50 | 29.7200 | 0.1900 | 23.3694 | 115.5100 | AID651703 |
| protein AF-9 isoform a | Homo sapiens (human) | AC50 | 2.3000 | 0.0800 | 8.3802 | 17.9800 | AID720495 |
| transforming acidic coiled-coil-containing protein 3 | Homo sapiens (human) | AC50 | 29.7200 | 0.1900 | 24.2333 | 115.5100 | AID651703 |
| HSP40, subfamily A [Plasmodium falciparum 3D7] | Plasmodium falciparum 3D7 | AbsAC1000_uM | 2.5220 | 0.1290 | 4.1169 | 11.3160 | AID540271 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (20)
Molecular Functions (4)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| guanyl-nucleotide exchange factor activity | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| protein binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| protein domain specific binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| cAMP binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (8)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| cortical actin cytoskeleton | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| plasma membrane | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| microvillus | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| endomembrane system | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| membrane | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| lamellipodium | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| filopodium | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| extracellular exosome | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (18)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID337171 | Antiviral activity against HIV1 HTLV-3B in human H9 cells after 3 days by p24 antigen capture assay | |||
| AID337172 | Cytotoxicity against human H9 cells | |||
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (16)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (37.50) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.76
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.76) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||